Journal: eNeuro

Article Title: New Mouse Lines That Drive Tetracycline-Controlled Gene Expression in a Small Subset of Spinal Cord Dorsal Horn Neurons

doi: 10.1523/ENEURO.0441-24.2025

Figure Lengend Snippet: GFP-positive cells express neuron-specific marker Elavl2. Cervical spinal cord sections from HB9-tTA;tetO-GFP double transgenic mice were analyzed. A , E , GFP signal. B , F , Elavl2 immunostaining. C , G , Merged image showcasing colocalization of Elavl2 and GFP signal. D , H , The area covered by a white square in enlarged 10 folds to showcase colocalization of Elavl2 and GFP fluorescent signal. I , J , Coronal section of the cervical region of the spinal cord stained for CGRP and DAPI. The tissues were from an HB9-tTA;tetO-GFP double transgenic mouse of Line 1 ( I ) and Line 4 ( J ), respectively. Scale bar, 10, 50, or 100 μm.

Article Snippet: The following primary antibodies were used in this study: Elavl2 primary antibody at a dilution of 1:250 (Proteintech, 14008-1-AP) and Anti-Calcitonin Gene Related Peptide (Sigma-Aldrich, C8198) at a dilution of 1:500.

Techniques: Marker, Transgenic Assay, Immunostaining, Staining

Journal: Acta Neuropathologica

Article Title: Nuclear depletion of RNA-binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis

doi: 10.1007/s00401-021-02374-4

Figure Lengend Snippet: ELAVL family members are also frequently abnormal but only in the presence of TDP-43 aggregates. ELAVL1 in control ( a ), sporadic ( b–d ), and SOD1 ( e ). Nuclear ELAVL1 expression is maintained or slightly reduced and, in the cytoplasm, can be seen either colocalizing or encapsulating TDP-43 aggregates or forming its own inclusions. ELAVL2 expression in control ( f ), sporadic ( g ), and C9orf72 ( h – j ). Nuclear ELAVL2 expression is maintained or reduce depending on the ALS sample and in the cytoplasm can be seen either colocalizing TDP-43 fibrillary aggregates ( h – j ), but not with speckles ( i ). ELAVL4 in control ( k – l ) and sporadic samples ( m – o ). Nuclear ELAVL4 expression is more diffuse in controls than other ELAVLS, and in ALS, it is reduced or depleted from the nucleus and it variably colocalizes with TDP-43 aggregates in the cytoplasm

Article Snippet: Primary antibodies were ELAVL3 (#55047-1-AP from Proteintech (lot number 09000021 was specific for biochemistry) and LS-C408905-50 from LsBio), TDP-43 mouse (#DR1075-100UG, 1:500; calbiochem), TDP-43 Rabbit (#10782-2-AP Rabbit Proteintech), HuR-Antibody (#11910-1-AP, Proteintech), ELAVL4 (#24992-1-AP Proteintech), ELAVL2 (#67097-1-AP Proteintech), and Ubiquitin (Ubi-1 ab7254, Abcam).

Techniques: Control, Expressing

Journal: Acta Neuropathologica

Article Title: Nuclear depletion of RNA-binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis

doi: 10.1007/s00401-021-02374-4

Figure Lengend Snippet: Summary of ELAVL family

Article Snippet: Primary antibodies were ELAVL3 (#55047-1-AP from Proteintech (lot number 09000021 was specific for biochemistry) and LS-C408905-50 from LsBio), TDP-43 mouse (#DR1075-100UG, 1:500; calbiochem), TDP-43 Rabbit (#10782-2-AP Rabbit Proteintech), HuR-Antibody (#11910-1-AP, Proteintech), ELAVL4 (#24992-1-AP Proteintech), ELAVL2 (#67097-1-AP Proteintech), and Ubiquitin (Ubi-1 ab7254, Abcam).

Techniques: Encapsulation

Journal: EBioMedicine

Article Title: MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

doi: 10.1016/j.ebiom.2019.102622

Figure Lengend Snippet: Target genes of miR-765 predicted with bioinformatics analysis in ccRCC. (A) Bioinformatic prediction of the top 15 candidate mRNAs targeting miR-765 via the TargetScan and miRDB platforms. (B) Column chart depicting the expression of the 6 target genes in TCGA-KIRC. (C) and (D) Overall survival (OS) and disease-free survival (DFS) analysis showed 3 target genes in TCGA-KIRC. (E) and (F) Univariate and multivariate survival analysis of OS and DFS indicated that high PLP2 expression was a potential independent prognostic factor in ccRCC patients. Data indicate the means ± SEM.**** P < 0.0001 ( t -test).

Article Snippet: Western blotting was performed according to the manufacturer's instructions with polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Bedford, MA, USA); proteins were blocked in PBS with 5% non-fat milk and incubated with antibodies against PLP2 (1:1000; A06255; Boster Biological Technology, Ltd., USA) and GAPDH (1:2000; BM3876; Wuhan Boster Biological Technology, Ltd., Wuhan, China) overnight.

Techniques: Expressing

Journal: EBioMedicine

Article Title: MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

doi: 10.1016/j.ebiom.2019.102622

Figure Lengend Snippet: Univariate and multivariate analyses of POUF2 and PLP2 mRNA level and patient overall survival.

Article Snippet: Western blotting was performed according to the manufacturer's instructions with polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Bedford, MA, USA); proteins were blocked in PBS with 5% non-fat milk and incubated with antibodies against PLP2 (1:1000; A06255; Boster Biological Technology, Ltd., USA) and GAPDH (1:2000; BM3876; Wuhan Boster Biological Technology, Ltd., Wuhan, China) overnight.

Techniques:

Journal: EBioMedicine

Article Title: MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

doi: 10.1016/j.ebiom.2019.102622

Figure Lengend Snippet: Univariate and multivariate analyses of POUF2 and PLP2 mRNA level and patient disease–free survival.

Article Snippet: Western blotting was performed according to the manufacturer's instructions with polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Bedford, MA, USA); proteins were blocked in PBS with 5% non-fat milk and incubated with antibodies against PLP2 (1:1000; A06255; Boster Biological Technology, Ltd., USA) and GAPDH (1:2000; BM3876; Wuhan Boster Biological Technology, Ltd., Wuhan, China) overnight.

Techniques:

Journal: EBioMedicine

Article Title: MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

doi: 10.1016/j.ebiom.2019.102622

Figure Lengend Snippet: PLP2 is significantly upregulated and predicts poor prognosis in the TCGA-KIRC dataset containing 72 normal tissues and 533 ccRCC tissues. (A) and (B) PLP2 was upregulated in cancer tissues compared with para-cancerous tissues. (C) PLP2 expression levels in five additional ccRCC data sets. The levels of PLP2 were compared across different clinicopathological parameters: (D) T stage, (E) lymphatic metastasis, (F) distant metastasis, (G) TNM stage (H) grade and (I) cancer-related death. Data indicate the means ± SEM. * P <0.05; ** P <0.01, *** P < 0.001, **** P < 0.0001 ( t -test), ### P <0.001(one-way ANOVA).

Article Snippet: Western blotting was performed according to the manufacturer's instructions with polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Bedford, MA, USA); proteins were blocked in PBS with 5% non-fat milk and incubated with antibodies against PLP2 (1:1000; A06255; Boster Biological Technology, Ltd., USA) and GAPDH (1:2000; BM3876; Wuhan Boster Biological Technology, Ltd., Wuhan, China) overnight.

Techniques: Expressing

Journal: EBioMedicine

Article Title: MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

doi: 10.1016/j.ebiom.2019.102622

Figure Lengend Snippet: PLP2 is involved in the biological pathogenesis of ccRCC. (A-D) PLP2 is upregulated in ccRCC tissues and renal cancer cells, as assessed by qRT-PCR and western blotting analysis. (E) Gene set enrichment analysis (GSEA) was used to compare high and low PLP2 expression groups in the TCGA database. Enrichment curves are shown for activated gene sets related to EMT and the G2M checkpoint. (F) Silencing of PLP2 with small RNA interference technology (si-PLP2-1 and si-PLP2-2). (G) si-PLP2 significantly repressed the migration of A498 cells. (H) GSEA enrichment curves showed that low PLP2 expression was associated with fatty acid triacylglycerol metabolism, lipid catabolic processes and neutral lipid metabolic processes. (H) and (I) Silencing of PLP2 significantly promoted neutral lipid catabolic processes and eliminated abnormal lipid accumulation in A498 cancer cells. Original magnification 200x. Data indicate the means ± SEM. ** P <0.01, *** P < 0.001 ( t -test).

Article Snippet: Western blotting was performed according to the manufacturer's instructions with polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Bedford, MA, USA); proteins were blocked in PBS with 5% non-fat milk and incubated with antibodies against PLP2 (1:1000; A06255; Boster Biological Technology, Ltd., USA) and GAPDH (1:2000; BM3876; Wuhan Boster Biological Technology, Ltd., Wuhan, China) overnight.

Techniques: Quantitative RT-PCR, Western Blot, Expressing, Migration

Journal: EBioMedicine

Article Title: MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

doi: 10.1016/j.ebiom.2019.102622

Figure Lengend Snippet: PLP2 is a direct target of miR-765. (A) and (B) PLP2 was negatively correlated with miR-765 in TCGA-KIRC and clinical ccRCC samples. (C-F) qRT-PCR and western blotting analysis of PLP2 expression in miR-765 mimic-, inhibitor- and NC-transfected A498 and Caki-1 cells. (G) and (H) Luciferase reporter assays showing approximately 50% decreased reporter activity after transfection of the wild-type PLP2 3′UTR reporter construct into A498 and Caki-1 cells in combination with miR-765 mimics. Data indicate the means ± SEM. * P <0.05; ** P <0.01 ( t -test).

Article Snippet: Western blotting was performed according to the manufacturer's instructions with polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Bedford, MA, USA); proteins were blocked in PBS with 5% non-fat milk and incubated with antibodies against PLP2 (1:1000; A06255; Boster Biological Technology, Ltd., USA) and GAPDH (1:2000; BM3876; Wuhan Boster Biological Technology, Ltd., Wuhan, China) overnight.

Techniques: Quantitative RT-PCR, Western Blot, Expressing, Transfection, Luciferase, Activity Assay, Construct

Journal: EBioMedicine

Article Title: MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

doi: 10.1016/j.ebiom.2019.102622

Figure Lengend Snippet: PLP2 reverses the function of miR-765 in renal cancer. (A) and (B) The expression of miR-765 and PLP2 was measured by qRT-PCR in A498 and Caki-1 cells. (C) The expression of PLP2 was measured by western blotting in A498 cells. (D) PLP2 overexpression impaired the effects of the miR-765 mimic on cell proliferation in A498 and Caki-1 cells. (E) and (F) PLP2 overexpression impaired the effects of the miR-765 mimic on migration and invasion in A498 cells. (G) and (H) PLP2 overexpression impaired the effects of the miR-765 mimic on lipid elimination in A498 cells. Original magnification 200x. Data indicate the means ± SEM. * P <0.05; ** P <0.01, *** P < 0.001 ( t -test).

Article Snippet: Western blotting was performed according to the manufacturer's instructions with polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Bedford, MA, USA); proteins were blocked in PBS with 5% non-fat milk and incubated with antibodies against PLP2 (1:1000; A06255; Boster Biological Technology, Ltd., USA) and GAPDH (1:2000; BM3876; Wuhan Boster Biological Technology, Ltd., Wuhan, China) overnight.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Over Expression, Migration

Journal: EBioMedicine

Article Title: MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

doi: 10.1016/j.ebiom.2019.102622

Figure Lengend Snippet: MiR-765 inhibits the malignant potential of renal cancer cells and eliminates lipids in renal cancer cells via PLP2 in vivo. (A), (B) and (C) Tumour size, weight and volume curves from the xenograft formation assay in which Caki-1 cells were subcutaneously injected into the flanks of mice and grown for 30 days. Tumour size was measured every 3 days. (D) PLP2 reversed the effect of miR-765 on tumour liver metastasis. (E) Oil Red O (ORO) staining showed PLP2 reversed the effect of miR-765 on tumour lipid accumulation. (F) PLP2 reversed the angiogenesis-inhibiting effect with vascular endothelial growth factor A (VEGFA) and tumour metastasis ability by Ki67 of miR-765. Original magnification x200. Data indicate the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001 ( t -test).

Article Snippet: Western blotting was performed according to the manufacturer's instructions with polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Bedford, MA, USA); proteins were blocked in PBS with 5% non-fat milk and incubated with antibodies against PLP2 (1:1000; A06255; Boster Biological Technology, Ltd., USA) and GAPDH (1:2000; BM3876; Wuhan Boster Biological Technology, Ltd., Wuhan, China) overnight.

Techniques: In Vivo, Tube Formation Assay, Injection, Staining

Journal: PPAR Research

Article Title: PPAR β / δ Agonism with GW501516 Increases Myotube PGC-1 α Content and Reduces BCAA Media Content Independent of Changes in BCAA Catabolic Enzyme Expression

doi: 10.1155/2023/4779199

Figure Lengend Snippet: Summary of primary antibodies used for western blot experiments.

Article Snippet: BCKDHa , RP , 1 : 1000 , ProSci , 31-325 , 50kd , BCKDHA Antibody.

Techniques: Western Blot